Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Johnson Matthey chair to step down as new CFO named

(Sharecast News) - Chemicals group Johnson Matthey has announced that its chair of seven years Patrick Thomas will step down later this year, while its CFO of four years will be replaced by the head of finance at DS Smith. The changes come as the business "enters the next phase of its transformation strategy to deliver a step change in cash generation, higher returns on capital and sustainable shareholder value," the company said in a statement.

Thomas has informed the board that he doesn't intend to seek re-election at the annual general meeting in July and so will step down from his position as chair, which he has held since 2018.

"It is now the right time to hand over to a new chair who can guide the company through the next phase of its strategy," Thomas said.

The search for a new chair has now begun, and the nomination committee continues to "consider opportunities to augment the board with new directors to reflect the group's transformation strategy", Johnson Matthey said.

Meanwhile, CFO Stephen Oxley is being replaced by DS Smith's finance director Richard Pike, who will join the company on 1 April.

Pike, who previously held senior finance positions at Biffa, AB Sugar, British Sugar and Boparan Holdings, is said to bring strong financial leadership and a deep understanding of manufacturing and recycling industries.

"Richard's proven track record of financial leadership will be critical as we continue to execute our transformation strategy, with a strong focus on delivering cash generation and creating value for all our stakeholders," said chief executive Liam Condon.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.